Corcept Therapeutics (CORT) Stock Forecast, Price Target & Predictions
CORT Stock Forecast
Corcept Therapeutics stock forecast is as follows: an average price target of $59.25 (represents a 25.61% upside from CORT’s last price of $47.17) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
CORT Price Target
The average price target for Corcept Therapeutics (CORT) is $59.25 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $78.00 to $38.00. This represents a potential 25.61% upside from CORT's last price of $47.17.
CORT Analyst Ratings
According to 6 Wall Street analysts, Corcept Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CORT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Corcept Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 30, 2024 | Joon Lee | Truist Financial | $76.00 | $43.93 | 73.00% | 61.12% |
| Aug 15, 2024 | Edward Nash | Canaccord Genuity | $78.00 | $34.71 | 124.72% | 65.36% |
| Jul 30, 2024 | David Amsellem | Piper Sandler | $38.00 | $36.12 | 5.20% | -19.44% |
| Jul 30, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $45.00 | $36.53 | 23.19% | -4.60% |
| Jun 12, 2024 | Edward Nash | Canaccord Genuity | $38.00 | $32.79 | 15.89% | -19.44% |
| Jun 10, 2024 | David Amsellem | Piper Sandler | $35.00 | $31.51 | 11.08% | -25.80% |
| Jun 04, 2024 | Joon Lee | Truist Financial | $65.00 | $31.59 | 105.76% | 37.80% |
| May 02, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $40.00 | $23.88 | 67.50% | -15.20% |
| Dec 09, 2022 | - | H.C. Wainwright | $30.00 | $23.01 | 30.38% | -36.40% |
| Aug 04, 2022 | - | H.C. Wainwright | $33.00 | $28.71 | 14.94% | -30.04% |
The latest Corcept Therapeutics stock forecast, released on Sep 30, 2024 by Joon Lee from Truist Financial, set a price target of $76.00, which represents a 73.00% increase from the stock price at the time of the forecast ($43.93), and a 61.12% increase from CORT last price ($47.17).
Corcept Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 4 | 8 |
| Avg Price Target | $76.00 | $59.25 | $51.88 |
| Last Closing Price | $47.17 | $47.17 | $47.17 |
| Upside/Downside | 61.12% | 25.61% | 9.99% |
In the current month, the average price target of Corcept Therapeutics stock is $76.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 61.12% increase as opposed to Corcept Therapeutics's last price of $47.17. This month's average price target is up 28.27% compared to last quarter, and up 46.49% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 25, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 18, 2024 | Sandler O'Neill | Buy | Buy | Hold |
| Sep 18, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Sep 18, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 15, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jul 30, 2024 | Truist Financial | Buy | Buy | Hold |
| Jul 30, 2024 | Sandler O'Neill | Underperform | Underperform | Hold |
| Jul 30, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 30, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 01, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Corcept Therapeutics's last stock rating was published by Canaccord Genuity on Sep 25, 2024. The company gave CORT a "Buy" rating, the same as its previous rate.
Corcept Therapeutics Financial Forecast
Corcept Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $135.41M | $123.60M | $117.72M | $105.65M | $103.06M | $101.73M | $103.39M | $93.69M | $98.82M | $96.13M | $91.59M | $79.44M | $85.73M | $86.33M | $88.56M | $93.25M | $87.89M | $81.50M | $72.26M | $64.83M | $57.66M | $27.60M |
| Avg Forecast | $233.90M | $197.76M | $182.52M | $177.71M | $178.45M | $171.98M | $155.14M | $141.19M | $129.27M | $119.71M | $109.60M | $104.89M | $105.08M | $107.57M | $101.00M | $98.88M | $100.57M | $97.19M | $86.84M | $91.81M | $90.36M | $90.87M | $90.13M | $87.00M | $87.67M | $78.00M | $70.88M | $69.29M | $65.90M | $20.70M |
| High Forecast | $233.90M | $197.76M | $182.52M | $177.71M | $178.45M | $177.70M | $155.14M | $141.19M | $129.27M | $120.13M | $109.60M | $104.89M | $105.08M | $107.57M | $101.00M | $98.88M | $100.57M | $97.19M | $86.84M | $91.81M | $90.36M | $90.87M | $90.13M | $87.00M | $87.67M | $78.00M | $70.88M | $69.29M | $79.08M | $24.84M |
| Low Forecast | $233.90M | $197.76M | $182.52M | $177.71M | $178.45M | $169.87M | $155.14M | $141.19M | $129.27M | $118.93M | $109.60M | $104.89M | $105.08M | $107.57M | $101.00M | $98.88M | $100.57M | $97.19M | $86.84M | $91.81M | $90.36M | $90.87M | $90.13M | $87.00M | $87.67M | $78.00M | $70.88M | $69.29M | $52.72M | $16.56M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | 1.05% | 1.03% | 1.07% | 1.01% | 0.98% | 0.95% | 1.02% | 0.95% | 0.98% | 0.99% | 1.05% | 0.87% | 0.95% | 0.95% | 0.98% | 1.07% | 1.00% | 1.04% | 1.02% | 0.94% | 0.88% | 1.33% |
Corcept Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $141.19M, with a low forecast of $141.19M, and a high forecast of $141.19M. CORT's average Quarter revenue forecast represents a 4.27% increase compared to the company's last Quarter revenue of $135.41M (Dec 23).
Corcept Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | $32.30M | $31.18M | $29.58M | $14.85M | $22.50M | $32.69M | $31.43M | $27.57M | $37.60M | $37.15M | $32.92M | $20.93M | $31.67M | $26.53M | $37.79M | $41.26M | $38.47M | $36.27M | $27.52M | $21.66M | $21.63M | $4.75M |
| Avg Forecast | $73.64M | $62.26M | $57.46M | $55.95M | $56.18M | $54.14M | $48.84M | $39.15M | $40.70M | $37.69M | $34.51M | $35.59M | $33.08M | $33.87M | $31.80M | $32.35M | $31.66M | $30.60M | $27.34M | $23.61M | $28.45M | $28.61M | $28.38M | $34.36M | $27.60M | $24.56M | $22.31M | $24.89M | $24.00M | $3.17M |
| High Forecast | $73.64M | $62.26M | $57.46M | $55.95M | $56.18M | $55.95M | $48.84M | $46.98M | $40.70M | $37.82M | $34.51M | $42.71M | $33.08M | $33.87M | $31.80M | $38.82M | $31.66M | $30.60M | $27.34M | $28.33M | $28.45M | $28.61M | $28.38M | $41.23M | $27.60M | $24.56M | $22.31M | $29.87M | $28.80M | $3.80M |
| Low Forecast | $73.64M | $62.26M | $57.46M | $55.95M | $56.18M | $53.48M | $48.84M | $31.32M | $40.70M | $37.44M | $34.51M | $28.47M | $33.08M | $33.87M | $31.80M | $25.88M | $31.66M | $30.60M | $27.34M | $18.89M | $28.45M | $28.61M | $28.38M | $27.49M | $27.60M | $24.56M | $22.31M | $19.91M | $19.20M | $2.53M |
| Surprise % | - | - | - | - | - | - | - | - | 0.79% | 0.83% | 0.86% | 0.42% | 0.68% | 0.97% | 0.99% | 0.85% | 1.19% | 1.21% | 1.20% | 0.89% | 1.11% | 0.93% | 1.33% | 1.20% | 1.39% | 1.48% | 1.23% | 0.87% | 0.90% | 1.50% |
1 analysts predict CORT's average Quarter EBITDA for Mar 24 to be $39.15M, with a high of $46.98M and a low of $31.32M. This is 21.20% upper than Corcept Therapeutics's previous annual EBITDA (Dec 23) of $32.30M.
Corcept Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 |
| Net Income | - | - | - | - | - | - | - | - | $31.36M | $31.17M | $27.36M | $15.88M | $16.60M | $34.61M | $27.41M | $22.80M | $32.05M | $30.47M | $26.52M | $23.46M | $25.99M | $21.63M | $28.33M | $30.07M | $29.38M | $26.34M | $20.19M | $18.27M | $17.46M | $4.39M |
| Avg Forecast | $77.87M | $50.06M | $38.38M | $35.32M | $31.43M | $31.36M | $25.59M | $32.18M | $28.71M | $24.29M | $16.69M | $29.26M | $26.66M | $26.03M | $26.33M | $26.60M | $25.03M | $23.92M | $18.36M | $26.82M | $18.36M | $23.36M | $24.75M | $25.97M | $29.11M | $22.06M | $20.30M | $22.12M | $19.64M | $2.93M |
| High Forecast | $77.87M | $50.06M | $38.38M | $35.32M | $31.43M | $39.50M | $25.59M | $38.62M | $31.01M | $28.70M | $16.69M | $35.11M | $26.66M | $26.03M | $26.33M | $31.92M | $25.03M | $23.92M | $18.36M | $32.18M | $18.36M | $23.36M | $24.75M | $31.16M | $29.11M | $22.06M | $20.30M | $26.55M | $23.57M | $3.51M |
| Low Forecast | $77.87M | $50.06M | $38.38M | $35.32M | $31.43M | $23.23M | $25.59M | $25.75M | $24.12M | $17.66M | $16.69M | $23.40M | $26.66M | $26.03M | $26.33M | $21.28M | $25.03M | $23.92M | $18.36M | $21.45M | $18.36M | $23.36M | $24.75M | $20.77M | $29.11M | $22.06M | $20.30M | $17.70M | $15.71M | $2.34M |
| Surprise % | - | - | - | - | - | - | - | - | 1.09% | 1.28% | 1.64% | 0.54% | 0.62% | 1.33% | 1.04% | 0.86% | 1.28% | 1.27% | 1.44% | 0.88% | 1.42% | 0.93% | 1.14% | 1.16% | 1.01% | 1.19% | 0.99% | 0.83% | 0.89% | 1.50% |
Corcept Therapeutics's average Quarter net income forecast for Mar 24 is $32.18M, with a range of $25.75M to $38.62M. CORT's average Quarter net income forecast represents a 2.64% increase compared to the company's last Quarter net income of $31.36M (Dec 23).
Corcept Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 |
| SG&A | - | - | - | - | - | - | - | - | $47.15M | $45.26M | $43.28M | $48.56M | $42.32M | $35.16M | $37.81M | $37.55M | $32.28M | $30.53M | $30.03M | $29.51M | $25.70M | $26.52M | $25.57M | $27.54M | $27.13M | $24.25M | $24.59M | $24.39M | $18.44M | $15.04M |
| Avg Forecast | $80.54M | $68.10M | $62.85M | $61.19M | $61.45M | $59.22M | $53.42M | $53.01M | $44.51M | $41.22M | $37.74M | $48.19M | $36.18M | $37.04M | $34.78M | $43.81M | $34.63M | $33.47M | $29.90M | $33.72M | $31.12M | $31.29M | $31.04M | $23.78M | $30.19M | $26.86M | $24.41M | $29.52M | $20.75M | $10.02M |
| High Forecast | $80.54M | $68.10M | $62.85M | $61.19M | $61.45M | $61.19M | $53.42M | $63.61M | $44.51M | $41.37M | $37.74M | $57.83M | $36.18M | $37.04M | $34.78M | $52.57M | $34.63M | $33.47M | $29.90M | $40.47M | $31.12M | $31.29M | $31.04M | $28.54M | $30.19M | $26.86M | $24.41M | $35.43M | $24.89M | $12.03M |
| Low Forecast | $80.54M | $68.10M | $62.85M | $61.19M | $61.45M | $58.49M | $53.42M | $42.41M | $44.51M | $40.95M | $37.74M | $38.55M | $36.18M | $37.04M | $34.78M | $35.05M | $34.63M | $33.47M | $29.90M | $26.98M | $31.12M | $31.29M | $31.04M | $19.02M | $30.19M | $26.86M | $24.41M | $23.62M | $16.60M | $8.02M |
| Surprise % | - | - | - | - | - | - | - | - | 1.06% | 1.10% | 1.15% | 1.01% | 1.17% | 0.95% | 1.09% | 0.86% | 0.93% | 0.91% | 1.00% | 0.88% | 0.83% | 0.85% | 0.82% | 1.16% | 0.90% | 0.90% | 1.01% | 0.83% | 0.89% | 1.50% |
Corcept Therapeutics's average Quarter SG&A projection for Mar 24 is $53.01M, based on 1 Wall Street analysts, with a range of $42.41M to $63.61M. The forecast indicates a 12.42% rise compared to CORT last annual SG&A of $47.15M (Dec 23).
Corcept Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 8 |
| EPS | - | - | - | - | - | - | - | - | $0.29 | $0.31 | $0.27 | $0.15 | $0.15 | $0.32 | $0.26 | $0.22 | $0.28 | $0.26 | $0.23 | $0.20 | $0.22 | $0.19 | $0.25 | $0.26 | $0.26 | $0.23 | $0.18 | $0.16 | $0.15 | $0.04 |
| Avg Forecast | $0.70 | $0.45 | $0.34 | $0.32 | $0.28 | $0.28 | $0.23 | $0.22 | $0.26 | $0.22 | $0.15 | $0.20 | $0.24 | $0.23 | $0.24 | $0.23 | $0.23 | $0.21 | $0.17 | $0.22 | $0.17 | $0.21 | $0.22 | $0.22 | $0.26 | $0.20 | $0.18 | $0.19 | $0.18 | $0.02 |
| High Forecast | $0.70 | $0.45 | $0.34 | $0.32 | $0.28 | $0.36 | $0.23 | $0.22 | $0.28 | $0.26 | $0.15 | $0.20 | $0.24 | $0.23 | $0.24 | $0.23 | $0.23 | $0.21 | $0.17 | $0.22 | $0.17 | $0.21 | $0.22 | $0.22 | $0.26 | $0.20 | $0.18 | $0.19 | $0.22 | $0.02 |
| Low Forecast | $0.70 | $0.45 | $0.34 | $0.32 | $0.28 | $0.21 | $0.23 | $0.22 | $0.22 | $0.16 | $0.15 | $0.20 | $0.24 | $0.23 | $0.24 | $0.23 | $0.23 | $0.21 | $0.17 | $0.22 | $0.17 | $0.21 | $0.22 | $0.22 | $0.26 | $0.20 | $0.18 | $0.19 | $0.14 | $0.02 |
| Surprise % | - | - | - | - | - | - | - | - | 1.12% | 1.42% | 1.80% | 0.76% | 0.63% | 1.37% | 1.10% | 0.95% | 1.24% | 1.21% | 1.39% | 0.92% | 1.33% | 0.90% | 1.12% | 1.17% | 0.99% | 1.16% | 0.99% | 0.84% | 0.83% | 2.00% |
According to 1 Wall Street analysts, Corcept Therapeutics's projected average Quarter EPS for Mar 24 is $0.22, with a low estimate of $0.22 and a high estimate of $0.22. This represents a -24.14% decrease compared to CORT previous annual EPS of $0.29 (Dec 23).
Corcept Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SNSE | Sensei Biotherapeutics | $0.42 | $5.50 | 1209.52% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| NUVB | Nuvation Bio | $2.43 | $6.75 | 177.78% | Buy |
| ERAS | Erasca | $2.80 | $7.00 | 150.00% | Buy |
| MLYS | Mineralys Therapeutics | $13.88 | $30.00 | 116.14% | Buy |
| NXTC | NextCure | $1.45 | $3.00 | 106.90% | Buy |
| RARE | Ultragenyx Pharmaceutical | $56.77 | $108.14 | 90.49% | Buy |
| KROS | Keros Therapeutics | $61.09 | $102.00 | 66.97% | Buy |
| IDYA | IDEAYA Biosciences | $30.69 | $48.20 | 57.05% | Buy |
| CYTK | Cytokinetics | $54.53 | $83.23 | 52.63% | Buy |
| MGTX | MeiraGTx | $5.94 | $9.00 | 51.52% | Buy |
| ANAB | AnaptysBio | $35.18 | $44.80 | 27.35% | Buy |
| EWTX | Edgewise Therapeutics | $35.51 | $45.00 | 26.72% | Buy |
| DYN | Dyne Therapeutics | $34.73 | $43.88 | 26.35% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| CORT | Corcept Therapeutics | $47.17 | $59.25 | 25.61% | Buy |
| AGIO | Agios Pharmaceuticals | $44.14 | $48.71 | 10.35% | Buy |
| HALO | Halozyme Therapeutics | $52.28 | $56.86 | 8.76% | Buy |
| INSM | Insmed | $74.27 | $76.25 | 2.67% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
CORT Forecast FAQ
Is Corcept Therapeutics a good buy?
Yes, according to 6 Wall Street analysts, Corcept Therapeutics (CORT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of CORT's total ratings.
What is CORT's price target?
Corcept Therapeutics (CORT) average price target is $59.25 with a range of $38 to $78, implying a 25.61% from its last price of $47.17. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Corcept Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CORT stock, the company can go up by 25.61% (from the last price of $47.17 to the average price target of $59.25), up by 65.36% based on the highest stock price target, and down by -19.44% based on the lowest stock price target.
Can Corcept Therapeutics stock reach $70?
CORT's highest twelve months analyst stock price target of $78 supports the claim that Corcept Therapeutics can reach $70 in the near future.
What is Corcept Therapeutics's current price target trend?
1 Wall Street analyst forecast a $76 price target for Corcept Therapeutics (CORT) this month, up 61.12% from its last price of $47.17. Compared to the last 3 and 12 months, the average price target increased by 25.61% and increased by 9.99%, respectively.
What are Corcept Therapeutics's analysts' financial forecasts?
Corcept Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $646.75M (high $652.48M, low $644.65M), average EBITDA is $198.31M (high $207.94M, low $189.82M), average net income is $120.56M (high $135.13M, low $105.99M), average SG&A $227.1M (high $239.67M, low $215.77M), and average EPS is $1.01 (high $1.09, low $0.941). CORT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $791.88M (high $791.88M, low $791.88M), average EBITDA is $249.31M (high $249.31M, low $249.31M), average net income is $201.63M (high $201.63M, low $201.63M), average SG&A $272.68M (high $272.68M, low $272.68M), and average EPS is $1.81 (high $1.81, low $1.81).
Did the CORT's actual financial results beat the analysts' financial forecasts?
Based on Corcept Therapeutics's last annual report (Dec 2023), the company's revenue was $482.38M, beating the average analysts forecast of $463.47M by 4.08%. Apple's EBITDA was $109.64M, missing the average prediction of $148.48M by -26.16%. The company's net income was $106.14M, beating the average estimation of $98.94M by 7.27%. Apple's SG&A was $184.26M, beating the average forecast of $171.67M by 7.34%. Lastly, the company's EPS was $1.02, beating the average prediction of $0.825 by 23.63%. In terms of the last quarterly report (Dec 2023), Corcept Therapeutics's revenue was $135.4M, beating the average analysts' forecast of $129.27M by 4.75%. The company's EBITDA was $32.3M, missing the average prediction of $40.7M by -20.64%. Corcept Therapeutics's net income was $31.36M, beating the average estimation of $28.71M by 9.20%. The company's SG&A was $47.15M, beating the average forecast of $44.51M by 5.93%. Lastly, the company's EPS was $0.29, beating the average prediction of $0.258 by 12.36%